Alarm As Novartis Exits Antibiotics Space
The Swiss major says that while the science for its antibacterial and antiviral research programs is compelling, "we have decided to prioritize our resources in other areas where we believe we are better positioned to develop innovative medicines."
You may also be interested in...
Deal Watch: Celgene Reworks Alliance With Jounce, Gaining Global Rights To Macrophage-Targeting Candidate
Revised agreement of 2016 collaboration returns all vopratelimab rights to Jounce. Gilead fortifies antiviral pipeline in deals with Novartis, Durect.
Novartis executives highlighted their stars from its refined pipeline during the company’s first R&D day since Vas Narasimhan took the helm and after a cull that reduced the firm’s development portfolio by 20%.
Repeat antibiotic entrepreneurs raised $33m to launch Qpex with assets from The Medicines Co. Also, Taiho increases VC fund to $300m and TP Therapeutics raises $80m.